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Pleuropulmonary blastoma is a rare childhood malignancy of lung mesenchymal cells that can remain dormant as epithelial cysts or
progress to high-grade sarcoma. Predisposing germline loss-of-function DICER1 variants have been described. We sought to
uncover additional contributors through whole exome sequencing of 15 tumor/normal pairs, followed by targeted resequencing,
miRNA analysis and immunohistochemical analysis of additional tumors. In addition to frequent biallelic loss of TP53 and mutations
of NRAS or BRAF in some cases, each case had compound disruption of DICER1: a germline (12 cases) or somatic (3 cases)
loss-of-function variant plus a somatic missense mutation in the RNase IIIb domain. 5p-Derived microRNA (miRNA) transcripts
retained abnormal precursor miRNA loop sequences normally removed by DICER1. This work both deﬁnes a genetic interaction
landscape with DICER1 mutation and provides evidence for alteration in miRNA transcripts as a consequence of DICER1 disruption
in cancer.
Oncogene (2014) 33, 5295–5302; doi:10.1038/onc.2014.150; published online 9 June 2014
INTRODUCTION
Pleuropulmonary blastoma (PPB) is a rare, aggressive sarcoma
arising from mesenchymal cells of the lung during early child-
hood. The classic initial stage of PPB (mean age at presentation
10 months) features dilated airspaces lined by lung epithelium
(Type I PPB). The mesenchymal cells within the walls of
the cysts have the potential to transform into high-grade,
sarcoma-forming cystic and solid (Type II PPB) or purely solid
(Type III PPB) masses by 3–4 years of age;
1 however, not
all cysts naturally progress to life-threatening sarcoma.
Germline loss-of-function variants in DICER1 have been described
in familial PPB,
2 and these patients variably show increased risk for
ovarian Sertoli–Leydig tumors, renal cystic nephromas, nodular
hyperplasia and carcinoma of the thyroid gland and an assort-
ment of other rare extrapulmonary benign or malignant
neoplastic conditions, thus implicating DICER1 as a tumor
suppressor.
2–9 Surprisingly, DICER1 expression is reportedly lost
in tumor-associated epithelium in some cases, but retained in the
tumor mesenchyme.
2 We sought to uncover additional and
cooperating genetic events driving PPB progression in tumor
mesenchyme and to investigate molecular consequences of
DICER1 mutation.
RESULTS
DICER1 incurs biallelic disruption in PPB
Analysis of exome sequence data from mesenchymal tissue from
15 PPBs (6 Type II, 9 Type III; Supplementary Table 1) with paired
normal DNA (88× mean coverage of 18 863 genes) uncovered 1.1
exonic mutations per megabase (0.85 non-silent). Despite the
young age of PPB patients, these mutation rates are more
consistent with adult cancers than pediatric malignancies.
10
The two cases with the highest mutation rates, 3.6 mutations
per Mb, had loss-of-function mutations in DNA repair genes:
BTBD12/SLX4 p.L1621fs in a Type III PPB and PARP1 c.1159+1A>G
in a Type II PPB that recurred following chemotherapy. In total,
623 somatic mutations were found in 568 genes (Supplementary
Table 2), of which only three were mutated at signiﬁcant
frequency (q⩽0.1, MutSig v1.5
11): DICER1, TP53 and NRAS
(Figure 1, Table 1 and Supplementary Table 3).
Somatic DICER1 missense mutations were found in all 15 cases
by exome sequence analysis, and in an additional 32 of 34 PPBs by
targeted sequencing of an extension cohort (Supplementary Table
4). Nearly all of these somatic mutations clustered in the RNase IIIb
domain (Figure 2), in some cases affecting amino acids identical to
those reported in ovarian Sertoli–Leydig tumors,
12 a tumor seen in
association with familial PPB. The single somatic mutation outside
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www.nature.com/oncthis region was in a case without a germline variant. This tumor
had two somatic events, a 10 bp frameshift insertion and an RNase
IIIb missense mutation. The most frequent mutation, p.
Gly1809Arg, was seen in seven of nine Type III PPBs by exome
sequencing and in 13 extension cases. Notably, this mutation has
not been reported in any other malignancy to date (Catalogue of
Somatic Mutations in Cancer v.68
13), suggesting it may be
characteristic of progressive PPB.
In addition to somatic missense mutations in DICER1, each of
the 15 whole exome sequencing cases also had loss of the
second DICER1 allele through one of several genetic mechanisms
(Figures 3a and e). Germline loss-of-function DICER1 sequence
variants were found in 12 of 15 cases: nine without further copy-
number alterations (Figure 3a), one with somatic deletion of the
predisposing germline allele (Figure 3b) and two with somatic,
arm-level gain of 14q that duplicated either the somatic missense
or germline loss-of-function allele (Figure 3c). One case without a
predisposing germline variant had two somatic mutations: a 10bp
frameshift insertion and an RNase IIIb missense mutation that was
also duplicated by copy-number gain (similar to Figure 3c). The
remaining two cases without a predisposing germline allele had
copy neutral loss-of-heterozygosity at the DICER1 locus owing to
somatic uniparental disomy of all (Figure 3d; PPB_15) or part
(Figure 3e; PPB_13, 14q21->qter) of chromosome 14. Sanger
sequencing of one case conﬁrmed that the germline and somatic
mutations occurred in trans (Supplementary Figure 1), consistent
with allele fractions observed in the tumor sequence data (0.2
germline loss-of-function variant, 0.68 somatic missense mutant).
These data suggest that DICER1 requires biallelic disruption,
functioning as a unique variant of a two-hit tumor suppressor
rather than through haploinsufﬁciency. However, retention of
some DICER1 activity appears to be necessary to ensure survival of
PPB cells, as no cases harbored two complete loss-of-function
variants and mutant alleles were often duplicated. Therefore, the
focused hotspot region of missense mutation in DICER1 appears to
be functionally distinct from simple loss-of-function variants found
through the gene body.
DICER1 RNase IIIb domain mutations lead to defective cleavage of
5p miRNAs from the pre-miRNA loop sequence
Double-stranded precursor miRNAs (pre-miRNAs) are normally
processed by DICER1 into three maturation products: two
potentially functional units derived from either the 5-prime (5p)
or 3-prime (3p) arm of the precursor (mature 5p and 3p miRNAs)
and the hairpin loop. In vivo studies on mouse mesenchymal
stem cells transfected with human DICER1 (hsDICER) mutant
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Figure 1. Matrix of frequent copy-number alterations and signiﬁcantly mutated genes derived from exome sequence data in each case. Cases
are in columns and genetic alterations are in rows with events color-coded as indicated. The loss-of-function category includes nonsense,
splice-site, insertion and deletion mutations. Copy-neutral LOH refers to chromosome- or arm-level loss-of-heterozygosity without a change in
copy number (for example, loss of the chromosome containing the wild-type allele and duplication of the chromosome containing the
mutant allele), as shown in Figure 3.
Table 1. Genes with signiﬁcant somatic mutation frequencies
Gene Description Mutations Patients
(n=15)
Unique sites Missense Nonsense, splice site
or frameshift
q-value
DICER1 Dicer 1, ribonuclease type III 16 15 7 15 1 7.8×10
−11
TP53 Tumor protein p53 7774 31 . 2 × 1 0
−10
NRAS Neuroblastoma RAS viral (v-ras)
oncogene homolog
2222 02 . 6 × 1 0
−4
(COSMIC only)
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14 had shown that the RNase IIIa domain of DICER1
serves a role in the removal of pre-miRNA loop sequences from
the 3p mature miRNA. The RNase IIIb domain cleaves the 5p
mature miRNA from the hairpin loop. Our microarray analysis of
miRNA expression levels found that primary PPB tumors had
signiﬁcant reduction in expression of 5p-derived miRNAs
(Figure 4a and Supplementary Figure 2), consistent with reported
DICER1 mutant expression proﬁles in Sertoli–Leydig tumors and in
mouse hsDICER1 constructs.
12,14,15 We subsequently conﬁrmed
this observation by quantitative polymerase chain reaction (PCR)
of seven miRNAs in 8–13 samples (Supplementary Figure
3 and Supplementary Table 5).
Because of the concern that oligonucleotide probes used for
expression arrays may still hybridize to 5p miRNAs with loop
sequence attached, we sought additional sequence conﬁrmation
of the speciﬁc defect in DICER1 function. Direct sequencing of
miRNA from primary tumor and cell line from PPB case 14
uncovered retention of pre-miRNA loop sequences joined to 5p
miRNAs compared with a normal lung ﬁbroblast cell line (Figures
4b and d and Supplementary Figure 4), providing direct evidence
that these mutations result in an inability to cleave the 5p end of
pre-miRNA hairpins and lead to retention of pre-miRNA loop
sequences in DICER mutant cancers.
Additional drivers of PPB development
Loss of TP53 occurred in 13 of 15 whole exome sequencing cases
(Figure 1 and Tables 1 and 2). Five cases had deletion of one 17p
allele, seven had deletion of one allele and mutation of the
remaining allele and one had homozygous deletion of TP53 owing
to an arm-level loss of 17p and a focal 130kb deletion. While
deletion of TP53 appears to occur early, most point mutations are
subclonal to DICER1 mutations, suggesting that only a sub-
population of PPB cells are malignant clones completely lacking
TP53. Analysis of TP53 expression by immunohistochemistry in 27
tumors conﬁrmed the presence of subclonal cell populations with
strong, diffuse staining in nine cases (Supplementary Figure 5).
TP53 expression by immunohistochemistry was consistent with
molecular status in 23 of 27 cases (Supplementary Table 6).
Two activating NRAS missense mutations that we identiﬁed in
PPB have been widely reported in other tumors (p.Gly13Arg and p.
Gln61Lys).
13 An additional case harbored an in-frame 9bp
insertion in the BRAF kinase domain (p.472_473insTVY), similar
to activating insertions reported in pilocytic astrocytoma
16 and
papillary thyroid cancer.
17 These mutations implicate increased
RAS signaling as a feature of PPB development, consistent with
mutation and expression proﬁling of other pediatric solid
tumors.
18
Analysis of copy-number variation using GISTIC2
19 uncovered
nine loci of signiﬁcant copy-number variation (q⩽0.1;
Table 2 and Supplementary Tables 7 and 8). Eight of these
correspond to whole chromosome (2+, 8+) or arm-level (10q−,
11q−, 17p−, 20q+) alterations. Oncogenes driven by ampliﬁca-
tion in other cancers include MYC on chromosome 8 and ALK,
MYCN and REL on chromosome 2.
20 Tumor suppressors on
frequently lost chromosome arms include PTEN and SUFU on
10q; WT1 on 11p; and TP53 and MAP2K4 on 17p.
20 In addition to
TP53, ATM, BCOR and SUFU had hemizygous loss-of-function
mutations, implicating them as additional targets of inactivation in
PPB. Four cases had a focal ampliﬁcation of 7.35 Mb on 19q13.13,
containing 196 genes of which >20% encode zinc-ﬁnger proteins.
The only gene in this region listed in the Cancer Gene Census
20 is
an unlikely ampliﬁcation target; tumor suppressor CEBPA,a
transcription factor that inhibits cyclin-dependent kinases 2 and
4.
21 This region is also signiﬁcantly ampliﬁed in esophageal
squamous cell carcinomas,
22 although the exact target of this
event remains unknown. This focal event may be indicative of a
more complex structural event not captured by our whole exome
sequencing assay, particularly as PPB karyotypes harbor frequent
translocations including two cases with 19q13 translocations
recorded in the International PPB Registry (http: //www.ppbreg-
istry.org).
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Figure 2. Location of somatic mutations and germline variants in signiﬁcantly mutated genes. Protein domains are as annotated from the
UniProt record indicated under each gene name. Somatic mutations are indicated by black text above the protein model, whereas germline
variants are indicated by green text below the protein model. Mutations detected in the extension cohort using targeted resequencing are
included in the counts of somatic DICER1 mutations.
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We describe here an extensive genomic analysis of the rare
embryonal tumor pleuropulmonary, identifying predisposing loss-
of-function DICER1 mutations coupled with partial loss-of-function
missense somatic DICER1 point mutations leading to defective
cleavage of 5p-derived miRNAs with retention of loop sequences.
TP53 is deleted and/or mutated in 13/15 cases and appears to be
an early event following DICER1 mutation in tumor cells. Copy-
number changes in critical genomic regions including PTEN, ATM
and WT1 are common. The identiﬁcation of RAS pathway
mutations suggests that activation of Ras signaling may be one
additional element that underlies progression from cysts to
tumors. Combined, these analyses conﬁrm a multistep genetic
pathogenesis in the lung mesenchymal cells of solid PPB, similar
to that seen in many adult tumors.
miRNA-seq analysis showed the effects of a somatic RNase IIIb
mutation on miRNA precursor molecules with correct cleavage of
mature miRNAs originating from the 3p arm and near total
absence of correct cleavage of mature miRNAs originating from
the 5p arm. Interestingly, one of the miRNAs whose 5p arm was
correctly cut was miR-451, a known target of Ago2 and not
DICER1.
23
Previous reports have shown gene expression proﬁles of DICER1
RNase IIIb mutant cells and tumors indicate derepression of genes
normally regulated by let-7 family and others producing an
oncogenic expression proﬁle.
14,15 We hypothesize that the
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Figure 3. Somatic chromosome 14 copy-number segments and allele fractions of variants heterozygous in matched normal. Data points are
the tumor allele fractions of heterozygous, non-reference alleles in the matched normal sample. Somatic deletion of the non-reference allele
results in tumor allele fractions near 0, whereas gain of the non-reference base or deletion of the reference base results in values approaching
1. Colored bars represent copy-number states inferred from fractional coverage values. Each panel depicts different combinations of copy-
number alteration and loss-of-heterozygosity detected by whole exome sequencing. (a) Copy quiet: Compound germline loss-of-function
(LOF) and somatic RNase IIIb missense mutation without further copy-number alteration (nine cases). (b) Wild-type deletion: Deletion of wild-
type allele resulting in hemizygosity for the somatic RNase IIIb missense mutation (PPB_11). (c) Trisomy: Copy-number gain of chromosome 14
resulting in duplication of RNase IIIb mutant allele and retention of germline LOF allele (two cases). An additional case has duplication of the
germline LOF allele and retention of the RNase IIIb mutant allele (PPB_5). (d) Chromosomal copy neutral loss-of-heterozygosity: Copy-neutral loss
of wild-type allele and duplication of entire chromosome 14 containing the somatic RNase IIIb missense mutation (PPB_15). (e) Arm-level copy
neutral loss-of-heterozygosity: Copy-neutral loss of wild-type allele and duplication of 14q containing the somatic RNase IIIb missense mutation
(PPB_13).
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Oncogene (2014) 5295–5302 © 2014 Macmillan Publishers Limitedretention of loop sequence results in premature degradation of the
5p-derived transcripts, as the ratio of 5p to 3p miRNAs was lower in
DICER1 mutant tumors compared with normal cells. Whether the
retention of the loop leads to degradation or improper loading of
the miRNA onto the RNA-induced silencing complex (RISC), or both,
is unclear and was not investigated in this study.
Altered miRNA proﬁles and resulting gene derepression may
not be the only tumorigenic mechanism in PPB. DICER1
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Figure 4. (a) Relative expression level of 5p- and 3p-derived miRNAs in 5 normal lung and 28 PPB tissues as measured by total microarray
intensities. Normal tissues (black) had higher expression of 5p miRNA compared with 3p miRNA, whereas all PPBs (red) appeared to have
lower overall expression of 5p miRNAs compared with normal tissues. (b–d) The fraction of reads with start and end points conﬁned to
functional units of 1595 miRNA primary transcripts. 5p and 3p Regions as annotated by miRbase build 19. Hairpin loop regions were deﬁned
as the genome segment between 5p and 3p regions. 5p+Loop+3p denotes reads that include 5p, loop and 3p sequence (that is, precursor
miRNAs). The fraction of reads corresponding to these regions in each miRNA individually is provided as Supplementary Figure 6 and
Supplementary Table 9. (b) In normal tissues, reads were primarily derived from mature 5p and 3p miRNAs sequenced, with higher expression
from 5p miRNA compared with 3p miRNA, consistent with the microarray data. (c) In addition to skewed ratio of 5p and 3p miRNA expression
compared with normal tissues, primary PPB tissue had increased fraction of reads containing 5p and loop sequences (5p+loop), and
full-length, pre-miRNAs (5p+loop+3p) (Supplementary Figure 4). (d) Owing to the presumed depletion of normal cells, the presence of
extended 5p miRNAs and pre-miRNAs is even clearer in a PPB cell line derived from the tissue displayed in (c).
Table 2. Chromosome regions of signiﬁcant somatic copy-number alteration
Chromosome arm Gain or loss Genes Ampliﬁcation cases Ampliﬁcation q-value Deletion cases Deletion q-value Candidate targets
2p Gain 924 6 3.0×10
−5 0 0.89 ALK, MYCN, REL
2q Gain 1556 6 3.1×10
−5 0 0.89
8p Gain 580 9 4.0×10
−9 1 0.82
8q Gain 859 10 4.8×10
−12 0 0.89 MYC
10q Loss 1268 0 0.90 9 3.5×10
−6 PTEN, SUFU
11p Loss 862 0 0.90 8 0.0024 WT1
17p Loss 683 0 0.90 13 0 TP53, MAP2K4
20q Gain 753 4 0.0023 0 0.97
19q13.13 Focal gain 196 4 4.5×10
−4 0 — Zinc-ﬁnger cluster
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repair and this has been postulated as a potential mechanism by
which DICER1 mutations may contribute to cancer.
24,25 The effect
of RNase IIIb mutations on other small RNA categories, including
those with a role in DNA repair, has not been studied. PPB does
appear to have a higher mutation rate (more on par with glioma
and breast carcinoma) than other pediatric cancers.
10,13 However,
given that TP53 mutations were also present in the large majority
of PPBs, it would be premature to attribute this high mutation rate
to an effect of mutant DICER1 on DNA repair alone.
Finally, biallelic mutations leading to complete loss of DICER1
function were not seen in any of the 49 cases in this report,
suggesting that one or more of the 3p mature miRNAs generated
from the retained RNase IIIa activity in DICER1 appear to be
necessary to ensure survival of PPB cells. If tumor cells are more
reliant on the cellular quantity of expressed 3p miRNAs for survival
than normal cells, then targeted antisense molecules to mature 3p
miRNAs may be an effective therapeutic approach.
MATERIALS AND METHODS
Cohort
Families were ascertained through the International PPB Registry (http:
//www.ppbregistry.org). All research subjects provided written consent to
the molecular and family history studies as approved by the Human
Research Protection Ofﬁces at Washington University and Children’s National
Medical Centers in St Louis, MO, USA and Washington, DC, USA, respectively.
Blood and saliva specimens were collected as a source of genomic DNA
through family visits made by the research team or mailed to Washington
University by the research subject or his/her health-care professional. DNA
was extracted from peripheral blood lymphocytes or saliva using standard
protocols. Snap frozen or formalin-ﬁxed, parafﬁn-embedded tumor tissue
was collected from treating institutions whenever available. All diagnoses of
PPB were conﬁrmed by pathologic review by DAH and LPD.
Exome sequencing and analysis
Exome sequencing was performed by the Broad Institute Genomics
Platform and analyzed using previously a described pipeline.
26 Brieﬂy,
reads were aligned using bwa,
27 followed by indel realignment and quality
score recalibration using the Genome Analysis Toolkit.
28 Somatic muta-
tions were detected using muTect
29 and indelocator, then annotated using
Oncotator (http: //www.broadinstitute.org/oncotator). MutSig v.1.5 was
used to detect signiﬁcantly mutated genes.
10 Copy-number calls were
derived from relative fractional sequence coverage of each exon compared
with a panel of normals. GISTIC2 was used to detect signiﬁcant copy-
number alterations.
19 These and other tools used for exome sequence
analysis are described at http: //www.broadinstitute.org/cancer/cga.
miRNA expression proﬁling
Whole snap frozen tumor tissue from 17 Type II (including two replicates)
and 11 Type III PPBs and adjacent normal tissue from ﬁve lungs (three
patients) was used for the miRNA microarray assay. Four 10µm sections
were cut with cryotome. One additional 5 µm slide was cut and stained
with hemtoxylin and eosin to assess tumor content and the percentage
of necrosis. Total RNA including small RNA was extracted using miRNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Puriﬁed total RNA was then quantiﬁed using NanoDrop ND2000
(NanoDrop Technologies, Wilmington, DE, USA). RNA quality was evaluated
with Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Only RNA
with RNA integrity number >6.0 was used for miRNA microarray assay.
The miRNA expression proﬁling was performed on GeneChip miRNA 2.0
Arrays containing 15644 probe sets (Affymetrix, Santa Clara CA,USA).
Brieﬂy, total RNA (300ng) was labeled with FlashTag Biotin HSR RNA
Labeling Kit (Genisphere Inc., Hatﬁeld, PA, USA) according to the
manufacturer’s protocol. Samples were applied to the array, hybridized
overnight and washed using the GeneChip Hybridization, Wash and Stain
Kit (Affymetrix). Array probe intensities were normalized using the Robust
Multichip Average function within the R (http: //www.r-project.org)
package 'affy'.
30 To annotate 5p- and 3p-derived sequences, Affymetrix
probe identiﬁers were mapped from miRbase build 10.1 to build 19 names.
R v. 2.15.1, including heatmap.2 and RColorBrewer libraries, was used to
calculate median and total probe intensities, and to cluster and visualize
normalized expression values (Supplementary Figure 2).
Quantitative real-time PCR
Total RNA (300ng) was reverse transcribed using the Qiagen miScript II RT
Kit (Qiagen) according to the manufacturer’s protocol. The mature
miRNA was then analyzed by real-time PCR using miScript PCR System
(Qiagen) on the StepOnePlus Real-Time PCR System (Applied Biosystems,
Grand Island, NY, USA). miRNA expression was analyzed using 2
−ΔΔCt
method. Relative mature miRNA expression was determined in reference
to the internal small nuclear RNA control SNORA73A. In statistical analysis,
the results were presented as mean±s.e.m., and assessed differences
between the two groups using Student’s t-test.
Phasing of DICER1 germline variant and somatic mutation
We used an allele-speciﬁc primer design to determine the cis–trans
relationships of germline and somatic mutations. The patient studied was
heterozyous for a germline mutation c. 4407_4410delTTCT (normal
germline allele sequence: 5′-GCTTTTGTAAAGAAAATCTCTCTTTCTCCTTTT
TCAAC-3'). The deleted 4 bases in the primer set are underlined. This
patient’s tumor harbored an additional somatic mutation, c. 5125G>A. To
amplify the germline wild-type allele, we used a forward allele-speciﬁc
primer (5′-GCTTTTGTAAAGAAAATCTCTCTTTCT-3′) and a reverse primer (5′-
CCACTATGCCGTCAGAACTC-3′). PCR was performed in a ﬁnal volume of
25μl containing 50ng DNA, 5pmol of each primer, 2μl dNTP, 2.5μlo f
10×PCR buffer and 2.5U ExTaq (Takara Bio, Otsu, Shiga, Japan). The
cycling proﬁle included an initial step at 94°C for 5 min ﬁrst, followed by 10
cycles including a denaturation step at 94°C for 55s, annealing step at 62°
C for 30s and an elongation step at 72°C for 3 min; then by 30 cycles,
which consisted of a denaturation step at 94°C for 55s, annealing step at
57.5°C for 45s and an elongation step at 72°C for 3min; and a ﬁnal
extension step at 72°C for 10min. The sequencing reactions were
performed using BigDye Sequencing Kit (v. 3.1) according to the
manufacturer’s protocol (Applied Biosystems, Grand Island, NY, USA). Data
were collected using an Applied Biosystems 3130xl Genetic Analyzer
(Applied Biosystems, Grand Island, NY, USA).
Validation set ion torrent sequencing and analysis
Formalin-ﬁxed, parafﬁn-embedded PPB tumors from 34 cases were used
for the validation set. Pure tumor areas were identiﬁed by hematoxylin and
eosin slide and 5mm cores were taken from the representative area for
each tumor. Following parafﬁn removal, DNA was extracted using the
Maxwell 16 formalin-ﬁxed, parafﬁn-embedded Tissue LEV DNA Puriﬁcation
Kit (Promega, Madison, WI, USA) on the Maxwell 16 Instrument (Promega).
DNA quality and quantity was assessed using a Nanodrop (ThermoFisher,
Wilmington, DE, USA) and Qubit (Qubit 2.0; Life Technologies, Grand Island,
NY, USA), respectively. Samples with bioanalyzer results yielding a narrow
peak indicating a loss of amplicons after library preparation were
interpreted as poor quality. Sequencing was performed on an Ion Torrent
Personal Genome Machine (Life Technologies, Carlsbad, CA, USA) using
standard protocols. A custom multiplex PCR panel was designed for the
coding regions of DICER1 and TP53 with an average amplicon length
o200bp (Custom Ampliseq; Life Techologies). Ten nanograms of starting
DNA was used for the initial PCR ampliﬁcation. The resulting amplicons
were then barcoded and ligated to adaptors (Ion Ampliseq Library Kit
2.0; Life Technologies). Templates were prepared using the ION PGM
Template OT2 200 Prep Kit and the One Touch 2 System (Life
Technologies). Sequencing was performed on a 318 chip (ION PGM
Sequencing 200 Kit v.2; Life Technologies) with an average of six samples
per chip plus one each positive and negative control samples to achieve an
average depth of coverage of 500 ﬁltered reads. Signal processing,
mapping and quality control was performed with Torrent Suite v.3.4.1 (Life
Technologies). Variant calls were made using Torrent Variant Caller Plugin
3.4 choosing somatic mutation workﬂow and default settings, call P-value
o0.05. BAM ﬁles containing raw reads were reviewed using Integrative
Genomics Viewer v.2.3.
31,32 Variants were annotated with Alamut mutation
HT software (Interactive Biosoftware, Rouen, France) and named using
HUGO nomenclature for DICER1 transcript NM_177438.2 and TP53
transcript NM_000546.5. For both DICER1 and TP53, nonsense, frameshift
and canonical splice-site mutations were considered loss of function. SIFT
(Sorting Intolerant From Tolerant) was used to assess the potential
signiﬁcance of predicted novel missense amino-acid substitutions.
33 TP53
mutations were additionally compared with the IARC TP53 Mutation
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set, http://p53.iarc.fr). We required a minimum ABQV ⩾20. We used allele
depth/ﬁltered depth to calculate allele frequency. We required a minimum
number of 100 reads total for each locus and minimum 10 reads of each
unique variant (except known SNPs). TP53 mutations classiﬁed as loss-of-
function and missense mutations with SIFT scores predictive of deleterious
effects are listed in Supplementary Table 6. Allele frequencies from the
common SNP c.215C>G; p.Pro72Arg were included, when present, as an
assessment for loss of heterozygosity.
miRNA-Seq
miRNA-enriched fractions separated from larger RNAs (>200nt) were
prepared using miRNeasy Mini Kit (Qiagen) according to the manufacturer’s
protocol. Enriched miRNA was quantitated on the Agilent 2100 Bioanalyzer
using the Small RNA Kit (Agilent). The miRNA library preparation was
performed using the Ion Total RNA-Seq Kit v.2 following standard protocols
(Life Technologies). Approximately 100ng of small RNA was used for the
initial hybridization and ligation procedure. Reverse transcription was then
performed and products were puriﬁed using the Magnetic Bead Cleanup
Module (Life Technologies). The cDNA was then further ampliﬁed and
puriﬁed to yield the ﬁnal library product. Templates were prepared using
the ION PGM Template OT2 200 Prep Kit and the One Touch 2 System (Life
Technologies). Sequencing of the miRNA was performed on a 316 chip (ION
PGM Sequencing 200 Kit v.2; Life Technologies). Signal processing, mapping
and quality control was performed with Torrent Suite v.3.4.2 (Life
Technologies). Reads were aligned to miRNA hairpin sequence reference
from miRBase (miRBase.org, Manchester, UK) and to the hg19/GRCh37
human genome reference sequence.
The Genome Analysis Toolkit DepthOfCoverage tool was used to
determine the read coverage at each base across 1595 miRNA primary
transcripts annotated by miRbase build 19. Coverage values were then
mapped to their percent location along the primary transcript and normalized
to a total fractional coverage for each miRNA (that is, the sum of fractional
coverage across each primary transcript equals one). These fractional
coverage distributions were then summed across all miRNAs and plotted as
Supplementary Figure 4. Genome coordinates from miRbase denoting the
location of miRNA 5p- and 3p-derived miRNAs within a primary transcript
were converted to percent locations for each miRNA and the distribution
plotted as a key to index the coverage distribution plots (see row 4 on
Supplementary Figure 4). miRNAs with both 5p (black) and 3p (red) elements
were depicted separately from miRNAs without these annotations (blue).
To count the number of reads corresponding to each annotated miRNA
component, we used the R package ‘rbamtools’ version 2.0 to extract the
mapping position of each read in the bam ﬁle that fell within an miRNA. To
remove adapter sequence and to account for uncertainty in the annotation
of the exact 5p and 3p coordinates, we trimmed 12bp from the start and
6bp from the end of each read. We then counted the number of reads
with trimmed start and end points located in all possible combinations of
5p, loop, 3p and unannotated regions.
Immunohistochemistry for p53
Immunohistochemistry for p53 was performed on 4µm sections of each of
the validation set tumors using the same block from which cores were
taken for DNA extraction. Using an automated stainer (BondMax; Leica
Biosystems, Buffalo Grove, IL, USA), anti-p53 antibody (clone Y5, prediluted,
rabbit monoclonal; Biocare Medical, Concord, CA, USA) was applied for
10min incubation following antigen retrieval in ER1 solution (citrate
based) for 30min (Leica, Buffalo Grove, IL, USA). Stains were reviewed by
three pathologists (DAH, CTR and LPD) and the percentage of tumor cell
nuclei with strong staining was recorded and compared with TP53
mutation status (Supplementary Figure 5 and Supplementary Table 6).
Strongly positive nuclei were considered to be likely associated with
missense mutations leading to delayed degradation.
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